7 results about "Dopamine receptor" patented technology

The present application relates to azapeptide compounds of formula (I) derived from melanocyte-stimulating hormone release-inhibiting factor-1. A method to obtain compounds of formula (I) is also described herein. The compounds of formula (I) have been shown to be suitable for the treatment of dopamine-related disorders of the central nervous system. These compounds showed enhanced potency as positive allosteric modulators of the dopamine D2 receptors in comparison with the melanocyte-stimulating hormone release- inhibiting factor-1 and, in general, do not exhibit meaningful cytotoxicity.

The invention belongs to the technical field of pharmaceutical chemicals, and provides a dopamine D3 receptor radioactive tracer and a preparation method and application thereof. According to the dopamine D3 receptor radiotracer (11C-YQA14) disclosed by the invention, a structure as shown in a formula 1 is used as a precursor compound, and gaseous 11C-CH3I is introduced under a closed condition to obtain the 11C-YQA14. The dopamine D3 receptor radioactive tracer has ideal affinity to a dopamine D3 receptor and has low affinity to a dopamine D2 receptor, so that the dopamine D3 receptor radioactive tracer can selectively recognize the dopamine D3 receptor and has low recognizability to the dopamine D2 receptor.

This invention relates to the application of a melanin-catalase nanocomposite (MAC) targeting intestinal mucosal neutrophils in the preparation of drugs for treating inflammatory bowel disease, belonging to the field of novel applications of nanomedicine. It addresses the challenges of catalase oral delivery being easily degraded and inactivated by gastrointestinal proteases and difficult to precisely target neutrophils. This invention is the first to discover a MAC prepared by in-situ polymerization of dopamine on the surface of catalase, which can be used for the treatment of inflammatory bowel disease. This nanocomposite, through oral delivery, precisely targets intestinal mucosal infiltrating neutrophils and maintains structural stability in the gastrointestinal fluid environment, effectively protecting catalase activity. It actively targets intestinal mucosal infiltrating neutrophils through the high affinity of melanin for dopamine D2 receptors, synergistically exerting a triple effect of hydrogen peroxide decomposition, hypochlorous acid scavenging, and iron ion chelation, effectively inhibiting the formation of extracellular traps in neutrophils.

The application discloses benzamide phenylpiperazine radioactive compounds and a preparation method and application thereof, and belongs to the field of radioactive drugs. 18 The F-labeled compound is simple in preparation method. The benzamide phenylpiperazine radioactive compound can be used as a dopamine D3 receptor targeted radioactive probe, and has the characteristics of excellent biological performance, high chemical purity and high specific activity.

This invention belongs to the field of medicinal chemistry, specifically disclosing a thienopyrimidine compound and its application as an allosteric antagonist of the dopamine D2 receptor (D2R). The target compounds of this invention contain a thieno[3,2-d]pyrimidine ring skeleton, the structural formula of which is shown in Formula 1. This invention uses GloSensor cAMP accumulation experiments to test the functional activity of the target compounds for D2R and to elucidate the allosteric mechanism of action of the new compounds on D2R. Pharmacological results show that all target compounds in this invention can negatively allosterically regulate the functional activity of the D2R endogenous ligand dopamine, i.e., all target compounds are negative allosteric modulators or allosteric antagonists of D2R.

An aza-ergoline derivative and a preparation method therefor and an application thereof. The derivative has a structure as shown in formula (I). The aza-ergoline derivative has good affinity, agonistic activity or selectivity to a dopamine D2 receptor.

Disclosed are a heterocyclic compound and a use thereof. More specifically, disclosed are a heterocyclic compound acting as a dual modulator for 5-HT2A and dopamine D2 receptors and a use thereof as a therapeutic agent for mental illness.